101 related articles for article (PubMed ID: 28455267)
1. Metabotropic glutamate receptor 5 mediates the suppressive effect of 6-OHDA-induced model of Parkinson's disease on liver cancer.
Xi SS; Bai XX; Gu L; Bao LH; Yang HM; An W; Wang XM; Zhang H
Pharmacol Res; 2017 Jul; 121():145-157. PubMed ID: 28455267
[TBL] [Abstract][Full Text] [Related]
2. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of metabotropic glutamate receptor 5 inhibits hepatoma development in a neurotoxin rotenone-induced Parkinson's disease model.
Bai XX; Gu L; Yang HM; Xi SS; Xia N; Zhang S; Zhang H
Toxicol Lett; 2018 May; 288():71-81. PubMed ID: 29458170
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
[TBL] [Abstract][Full Text] [Related]
5. PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.
Luo WY; Xing SQ; Zhu P; Zhang CG; Yang HM; Van Halm-Lutterodt N; Gu L; Zhang H
Neurotherapeutics; 2019 Jul; 16(3):761-783. PubMed ID: 31073978
[TBL] [Abstract][Full Text] [Related]
6. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.
Xia N; Zhang Q; Wang ST; Gu L; Yang HM; Liu L; Bakshi R; Yang H; Zhang H
Free Radic Biol Med; 2015 Dec; 89():567-80. PubMed ID: 26454081
[TBL] [Abstract][Full Text] [Related]
7. Activation of type 5 metabotropic glutamate receptor promotes the proliferation of rat retinal progenitor cell via activation of the PI-3-K and MAPK signaling pathways.
Zhang Z; Hu F; Liu Y; Ma B; Chen X; Zhu K; Shi Y; Wei T; Xing Y; Gao Y; Lu H; Liu Y; Kang Q
Neuroscience; 2016 May; 322():138-51. PubMed ID: 26902516
[TBL] [Abstract][Full Text] [Related]
8. Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Crabbé M; Van der Perren A; Weerasekera A; Himmelreich U; Baekelandt V; Van Laere K; Casteels C
Neurobiol Aging; 2018 Jan; 61():82-92. PubMed ID: 29055799
[TBL] [Abstract][Full Text] [Related]
9. mGluR5 Allosteric Modulation Promotes Neurorecovery in a 6-OHDA-Toxicant Model of Parkinson's Disease.
Farmer K; Abd-Elrahman KS; Derksen A; Rowe EM; Thompson AM; Rudyk CA; Prowse NA; Dwyer Z; Bureau SC; Fortin T; Ferguson SSG; Hayley S
Mol Neurobiol; 2020 Mar; 57(3):1418-1431. PubMed ID: 31754998
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson's disease.
Zhang YN; Fan JK; Gu L; Yang HM; Zhan SQ; Zhang H
J Neuroinflammation; 2021 Jan; 18(1):23. PubMed ID: 33461598
[TBL] [Abstract][Full Text] [Related]
11. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Black YD; Xiao D; Pellegrino D; Kachroo A; Brownell AL; Schwarzschild MA
Neurosci Lett; 2010 Dec; 486(3):161-5. PubMed ID: 20854878
[TBL] [Abstract][Full Text] [Related]
13. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA.
Nandhu MS; Paul J; Kuruvila KP; Abraham PM; Antony S; Paulose CS
Mol Cell Biochem; 2011 Jul; 353(1-2):47-57. PubMed ID: 21384157
[TBL] [Abstract][Full Text] [Related]
14. Enhanced glutamate, IP3 and cAMP activity in the cerebral cortex of unilateral 6-hydroxydopamine induced Parkinson's rats: effect of 5-HT, GABA and bone marrow cell supplementation.
Nandhu MS; Paul J; Kuruvilla KP; Malat A; Romeo C; Paulose CS
J Biomed Sci; 2011 Jan; 18(1):5. PubMed ID: 21235809
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer.
Yang HM; Cheng YZ; Hou TZ; Fan JK; Gu L; Zhang JN; Zhang H
Arch Biochem Biophys; 2023 Aug; 744():109698. PubMed ID: 37487948
[TBL] [Abstract][Full Text] [Related]
16. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator-associated ligand protects dopaminergic neurons by differentially regulating metabotropic glutamate receptor 5 in the progression of neurotoxin 6-hydroxydopamine-induced Parkinson's disease model.
Wang Y; Gu L; Yang HM; Zhang H
Neurotoxicology; 2021 May; 84():14-29. PubMed ID: 33571554
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
De Leonibus E; Managò F; Giordani F; Petrosino F; Lopez S; Oliverio A; Amalric M; Mele A
Neuropsychopharmacology; 2009 Feb; 34(3):729-38. PubMed ID: 18704096
[TBL] [Abstract][Full Text] [Related]
19. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
20. Constitutive downregulation protein kinase C epsilon in hSOD1
Vergouts M; Doyen PJ; Peeters M; Opsomer R; Hermans E
Glia; 2018 Apr; 66(4):749-761. PubMed ID: 29266405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
